Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer (PROJECTION)

  • End date
    Mar 1, 2025
  • participants needed
  • sponsor
    Ludwig-Maximilians - University of Munich
Updated on 25 April 2022
cancer chemotherapy
resectable pancreatic cancer
pancreatic neoplasm


This is a non-randomized, multicenter, non-interventional study in patients with resectable PDAC. The patients are allocated to two observation groups according preoperative presence of ctDNA (Group A) or absence of detectable ctDNA (Group B) as determined in a liquid biopsy. After successful surgery of their pancreatic tumor and completion of local histological evaluation, tissue samples will be analyzed with regard to their mutational status with. Within 14 days before start of adjuvant tumor therapy another liquid biopsy will be taken to reassess the level of ctDNA after surgery.

Patients will be monitored for disease recurrence according to harmonized, institutional standards using clinical, laboratory and (cross-sectional) imaging modalities. Accordingly, patients will be assessed every three months in the first eighteen months after surgery and every six months thereafter or based on clinical need for 36 months after the date of surgery Follow up will be documented until occurrence of relapse (or death if death occurs earlier than relapse/progression) for a maximum of 36 months after the date of surgery.

Condition Pancreas Cancer
Treatment Liquid Biopsy
Clinical Study IdentifierNCT04246203
SponsorLudwig-Maximilians - University of Munich
Last Modified on25 April 2022


Yes No Not Sure

Inclusion Criteria

Adult patients ≥ 18 years of age
Pancreatic mass, suspicious of pancreatic cancer, deemed resectable and resection planned
Patient deemed medically fit for adjuvant chemotherapy by the investigator
Patient's legal capacity to consent to study participation
Signed and dated informed consent to participate in the study

Exclusion Criteria

Non-resectable disease as determined by a local tumor board
Metastatic pancreatic disease
Previous neoadjuvant chemotherapy
Previous neoadjuvant radiotherapy
Histology other than PDAC such as acinar, neuroendocrine, mixed histology etc. in the resection specimen
Malignant disease other than PDAC within previous year (exception: patients with adequately treated and completely resected basal cell or squamous cell skin cancer; in situ cervical, breast or prostate cancer within previous year may be included)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note